Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19764845 | 1.00 | NAALAD2 (0.36) | NAALAD2HDAC1TSHRALDH1A1FPR2 | |
| SCHEMBL25761623 | 1.00 | NAALAD2 (0.36) | NAALAD2HDAC1TSHRALDH1A1FPR2 | |
| SCHEMBL23373592 | 0.83 | RNPEP (0.35) | NAALAD2HDAC1ALDH1A1FPR2 | |
| SCHEMBL25870207 | 0.83 | RNPEP (0.35) | NAALAD2HDAC1ALDH1A1FPR2 | |
| SCHEMBL16750132 | 0.82 | TSHR (0.38) | NAALAD2TSHRALDH1A1FPR2CYP2D6 | |
| SCHEMBL22891945 | 0.78 | DGAT1 (0.34) | — | |
| SCHEMBL26996992 | 0.78 | DGAT1 (0.34) | — | |
| SCHEMBL22891947 | 0.75 | TSHR (0.33) | TSHR | |
| SCHEMBL21507151 | 0.74 | CYP2D6 (0.41) | NAALAD2HDAC1ALDH1A1FPR2CYP2D6 | |
| SCHEMBL24613313 | 0.74 | CYP2D6 (0.41) | NAALAD2HDAC1ALDH1A1FPR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872217-B2 | Indanes as PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11135210-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-10919852-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200375962-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CHEMOCENTRYX, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | NAALAD2 1983/4885HDAC1 509/4885TSHR 352/4885 |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | NAALAD2 2997/4885HDAC1 159/4885TSHR 2425/4885 |
| US-20200375962-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | NAALAD2 3873/4885HDAC1 415/4885TSHR 146/4885 |
| US-11872217-B2 | Indanes as PD-L1 inhibitors | CD274, PDCD1, PDCD1LG2 | NAALAD2 3718/4885HDAC1 208/4885TSHR 239/4885 |
| US-11135210-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | NAALAD2 3873/4885HDAC1 415/4885TSHR 146/4885 |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | PDCD1, CD274, PDCD1LG2 | NAALAD2 4098/4885HDAC1 1813/4885TSHR 3202/4885 |
| US-10919852-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | NAALAD2 1983/4885HDAC1 509/4885TSHR 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.